2. Leung DY, Siegel RL, Grady S, Krensky A, Meade R, Reinherz EL, et al. Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. Clin Immunol Immunopathol 1982;23:100–112.
3. Furukawa S, Matsubara T, Motohashi T, Tsuda M, Sugimoto H, Yabuta K. Immunological abnormalities in Kawasaki disease with coronary artery lesions. Acta Paediatr Jpn 1991;33:745–751.
4. de Inocencio J, Hirsch R. The role of T cells in Kawasaki disease. Crit Rev Immunol 1995;15:349–357.
5. Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child 1976;130:599–607.
6. Barone SR, Pontrelli LR, Krilov LR. The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: use of clinical features and a rapid direct fluorescent antigen test. Arch Pediatr Adolesc Med 2000;154:453–456.
7. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006;21:778–781.
8. Wirojanan J, Sopontammarak S, Vachvanichsanong P. Sterile pyuria in Kawasaki disease. Pediatr Nephrol 2004;19:363
10. Salcedo JR, Greenberg L, Kapur S. Renal histology of mucocutaneous lymph node syndrome (Kawasaki disease). Clin Nephrol 1988;29:47–51.
11. Veiga PA, Pieroni D, Baier W, Feld LG. Association of Kawasaki disease and interstitial nephritis. Pediatr Nephrol 1992;6:421–423.
12. Bonany PJ, Bilkis MD, Gallo G, Lago N, Dennehy MV, Sosa del Valle JM, et al. Acute renal failure in typical Kawasaki disease. Pediatr Nephrol 2002;17:329–331.
13. Nardi PM, Haller JO, Friedman AP, Slovis TL, Schaffer RM. Renal manifestations of Kawasaki's disease. Pediatr Radiol 1985;15:116–118.
14. Lande MB, Gleeson JG, Sundel RP. Kawasaki disease and acute renal failure. Pediatr Nephrol 1993;7:593
15. Senzaki H, Suda M, Noma S, Kawaguchi H, Sakakihara Y, Hishi T. Acute heart failure and acute renal failure in Kawasaki disease. Acta Paediatr Jpn 1994;36:443–447.
17. Heldrich FJ, Jodorkovsky RA, Lake AM, Parnes CA. Kawasaki syndrome: HUS and HSP complicating its course and management. Md Med J 1987;36:764–766.
18. Lee BW, Yap HK, Yip WC, Giam YC, Tay JS. Nephrotic syndrome in Kawasaki disease. Aust Paediatr J 1989;25:241–242.
19. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708–1733.
20. Guignard JP, Santos F. Avner ED, Harmon WE, Niaudet P,Laboratory investigations. editors. Pediatric nephrology. 2004;5th ed. Philadelphia: Lippincott Williams & Wilkins, :399–424.
21. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984;104:849–854.
22. Uehara R, Yashiro M, Hayasaka S, Oki I, Nakamura Y, Muta H, et al. Serum alanine aminotransferase concentrations in patients with Kawasaki disease. Pediatr Infect Dis J 2003;22:839–842.
23. Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002;323:121–128.
24. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312–318.
25. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007;27:197–205.
26. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006;48:712–719.
27. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416–1421.
28. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;52:595–605.
29. Endre ZH, Westhuyzen J. Early detection of acute kidney injury: emerging new biomarkers. Nephrology (Carlton) 2008;13:91–98.
30. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007;212:209–217.
31. Berggard I, Bearn AG. Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids. J Biol Chem 1968;243:4095–4103.
32. Rosner MH, Bolton WK. Renal function testing. Am J Kidney Dis 2006;47:174–183.
33. Tack ED, Perlman JM, Robson AM. Renal injury in sick newborn infants: a prospective evaluation using urinary beta 2-microglobulin concentrations. Pediatrics 1988;81:432–440.
34. Schentag JJ, Plaut ME. Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. Kidney Int 1980;17:654–661.
35. Ohta K, Seno A, Shintani N, Kato E, Yachie A, Seki H, et al. Increased levels of urinary interleukin-6 in Kawasaki disease. Eur J Pediatr 1993;152:647–649.
36. Wang JN, Chiou YY, Chiu NT, Chen MJ, Lee BF, Wu JM. Renal scarring sequelae in childhood Kawasaki disease. Pediatr Nephrol 2007;22:684–689.